Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
NCT Number: NCT05236894
This clinical trial estimates the abuse liability of nicotine pouches with varying nicotine concentrations relative to cigarette smoking in Appalachian, Ohio and Ohio smokers. Nicotine pouches are a novel tobacco product with potential to reduce or increase the harm of tobacco use. Evaluating nicotine pouches abuse liability among smokers in Ohio including the unique demographic of Appalachia may clarify the public health effect of NPs in Appalachian Ohio and across Ohio. Results may inform public health efforts, policy, and clinical care aimed at reducing tobacco-related disparities.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Early Phase 1
Columbus, Ohio, 43210, United States
Aim 1:
PRIMARY OBJECTIVE:
I. To estimate the abuse liability of nicotine pouches (NPs) with varying nicotine concentrations relative to cigarette smoking.
SECONDARY OBJECTIVE:
I. To clarify the public health effect of NPs in Appalachian Ohio.
EXPLORATORY OBJECTIVES:
I. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring nicotine pharmacokinetics.
II. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring subjective effects.
III. To estimate the abuse liability of NPs with varying nicotine concentrations relative to cigarette smoking by measuring intentions to use and switch to NPs.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive lower dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3.
ARM II: Patients receive higher dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
ARM III: Patients smoke usual brand of cigarettes, taking one puff every 30 seconds over 5 minutes at visits 1, 2, and 3.
Aim 2:
PRIMARY OBJECTIVE:
I. To understand the pharmacokinetic difference between tobacco-derived and synthetic NPs.
SECONDARY OBJECTIVE:
I. To clarify the public health effect of NPs on adult smokers
EXPLORATORY OBJECTIVES:
I. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring nicotine pharmacokinetics.
II. To understand the differences in abuse liability between tobacco-derived and synthetic NPs by measuring subjective effects.
III. To estimate the abuse liability of tobacco-derived vs. synthetic NPs by measuring intentions to use and switch to NPs.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: Patients receive a 3mg dose nicotine pouch orally (PO) over 30 minutes at visits 1, 2, and 3.
ARM II: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
ARM III: Patients receive a 3mg dose nicotine pouch PO over 30 minutes at visits 1, 2, and 3.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Aim 1 Inclusion Criteria:
Exclusion criteria
Aim 2 Inclusion Criteria:
Exclusion criteria
Smoke preferred brand of cigarette
Given lower dose nicotine pouch
Other names: ZYN
Ancillary studies
Time frame: Up to 6 months
Time frame: Up to 6 months
Data collected will show if NPs are a viable substitute for cigarette smoking.
Time frame: Up to 6 months
Time frame: Up to 6 months
We measure withdrawal relief using the Minnesota Withdrawal Scale (MNWS). We administer this questionnaire at each timepoint along the standardized scale of t=0, t=5, t=15, t=30, t=60 and t=90. The MNWS includes a minimum value of "none" and a maximum value or "severe." The higher scores indicate increased withdrawal symptoms and lower scores indicate lessened or no withdrawal symptoms.
Time frame: Up to 6 months
Product appeal will be assessed using several scales, including the Modified E-Cigarette Smoking Questionnaire (mCEQ), the Product Evaluation Scale (PES), the Adapted Drug Effects Liking Scale, and the Study Product Effects Liking Scale which are administered after the final timepoint of each study visit. For both the mCEQ and PES, the minimum scale value is "not at all" and the maximum scale value is "extremely." Higher scores can mean both better or worse depending on the question. Ex: "Was using your smokeless tobacco satisfying?" and "Did using your smokeless tobacco make you nauseous?" are both questions on each scale, so a higher score would vary in meaning based on the question. For the Adapted Drug Effects Liking and Study Product Effects Liking scales, minimum values include "not at all" and maximum value includes "very pleasant." With the exception of one question on the Study Product Effects Liking Scale, a higher score indicates increased enjoyment of the product.
Time frame: Up to 6 months
Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product on plasma nicotine delivery.
Time frame: Up to 6 months
Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product on subjective effects.
Time frame: Up to 6 months
Will use linear or logistic mixed effects regression models (with a random subject effect) to assess the main effects of product behavioral intentions.
Time frame: Up to 6 months
Public health impact of NPs in adult smokers as an alternative for cigarette smoking.
Ohio State University Comprehensive Cancer Center
Other
Examining the Appeal of Nicotine Pouches in Ohio Appalachia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06038526
Cigarette Smoking-Related Carcinoma, Lung Carcinoma
Columbus, Ohio, United States
View Trial DetailsNCT05825001
Cigarette Smoking-Related Carcinoma
Buffalo, New York, United States
View Trial DetailsNCT06230159
Cigarette Smoking-Related Carcinoma
Columbus, Ohio, United States
View Trial DetailsNCT03856515
Cigarette Smoking-Related Carcinoma
Houston, Texas, United States
View Trial Details